PharosAI and 10x Genomics collaborate to revolutionize cancer research with spatial biology and AI
10x Genomics, Inc. announced that PharosAI will use the 10x Genomics Xenium spatial platform to build one of the world's most comprehensive multimodal cancer datasets and pair them with advanced AI models and analytical capabilities.
PharosAI is set to deliver a nexus of large-scale, AI-ready datasets, computational models and analytical tools to accelerate earlier diagnosis, enable precision therapies and speed the discovery of new treatments.
PharosAI brings together King's College London, Queen Mary University of London, Guy's and St Thomas' NHS Foundation Trust and Barts Health NHS Trust in a joint venture that combines clinical expertise, academic leadership and advanced technologies. By leveraging 10x Genomics' Xenium spatial platform, PharosAI intends to transform decades of archived NHS cancer samples into high-resolution, multimodal datasets that could be used by researchers, clinicians and innovators worldwide to power AI models for diagnosis and drug discovery to improve patient care and outcomes.
The initiative will launch with a major focus on breast cancer, before expanding to lung and pancreatic cancer, with plans to include thousands of clinical tissue samples. By combining genomic, transcriptomic, imaging and spatial biology data, and linking them with a suite of custom AI models and analytical capabilities, PharosAI will produce AI-ready datasets capable of revealing patterns that have remained hidden until now. With Xenium providing spatial insights and advanced AI models uncovering new biology, researchers will be able to ask bigger questions and move faster toward the discovery of new diagnostics and therapies.
To support a study of this scale, PharosAI required a spatial platform capable of delivering reproducible results across thousands of archival tissues. Xenium's high-throughput workflow, combined with the ability to generate custom-designed gene panels in collaboration with 10x teams, enabled the consortium to configure assays aligned with the molecular features most relevant to specific cancers.
Importantly, PharosAI will democratize access to these datasets, ensuring they are securely available to a broad community of researchers and innovators.
